A UK-wide analysis of the use of reversal agents in 198 patients on direct oral anticoagulants prior to urgent procedures
Molly Murphy, Michala Pettitt, Jasmine Makker, David J. Sutton et autres
Background: Direct oral anticoagulants (DOACs) are widely prescribed but present challenges when patients require urgent invasive procedures. While idarucizumab is licensed for preprocedural reversal of dabigatran, 4-factor prothrombin complex concentrates (4F-PCCs) are often used off-label for oral factor (F)Xa inhibitors. Objectives: We …
0 citations
Research and Practice in Thrombosis and Haemostasis